Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 929Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Lessons Learned from Two Decades of Anticancer Drugs
Zhichao Liu,Brian Delavan,Ruth Roberts,Weida Tong
Trends in Pharmacological Sciences.2017;38(10)852
[DOI]
2[18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment
Dmitry Soloviev,David Lewis,Davina Honess,Eric Aboagye
European Journal of Cancer.2012;48(4)416
[DOI]
3Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Jean-Marie Michot,Lina Benajiba,Laura Faivre,Capucine Baldini,Lelia Haddag,Clement Bonnet,Christophe Massard,Frederic Bigot,Camille Bigenwald,Benjamin Verret,Zo A. P. Thomas,Andrea Varga,Anas Gazzah,Antoine Hollebecque,David Ghez,Julien Lazarovici,Rastilav Balheda,Aurore Jeanson,Sophie Postel-Vinay,Alina Danu,Jean-Charles Soria,Xavier Paoletti,Vincent Ribrag
Investigational New Drugs.2018;36(1)62
[DOI]
4Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials
Margaret S. Landis
Investigational New Drugs.2017;25(1)297
[DOI]
5Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?
Zhe Li,Qin Li,Jun Wu,Manyuan Wang,Junxian Yu
Molecules.2016;21(10)1331
[DOI]
6Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?
Luz Romero,Jos Miguel Vela
Molecules.2014;21(10)59
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal